Anaptysbio, Inc. ANAB
What this company does
Written from the business description in ANAPTYSBIO, INC's annual report to the U.S. Securities and Exchange Commission, filed 3 March 2026. Every sentence was checked against that document before publication.
Revenue compounded at +25.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 24 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.2 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.0 | −0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | 0.0 | −0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.46 | −5.12 | −6.08 | −4.57 | −2.11 | −0.73 | −3.60 | −2.50 | −1.52 | −1.62 | −2.12 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −24.5 | −182.7 | −93.4 | −41.6 | −15.3 | −5.0 | −21.8 | −15.5 | −22.3 | · | · |
| Shares out B | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 11 of 19 fiscal years. 34 checks could not be computed.